The mysteries of menopause and urogynecologic health: clinical and scientific gaps

Menopause. 2019 Jan;26(1):103-111. doi: 10.1097/GME.0000000000001209.

Abstract

Objectives: A significant body of knowledge implicates menopausal estrogen levels in the pathogenesis of the common pelvic floor disorders (PFDs). These health conditions substantially decrease quality of life, increase depression, social isolation, caregiver burden, and economic costs to the individuals and society.

Methods: This review summarizes the epidemiology of the individual PFDs with particular attention to the understanding of the relationship between each PFD and menopausal estrogen levels, and the gaps in science and clinical care that affect menopausal women. In addition, we review the epidemiology of recurrent urinary tract infection (rUTI)-a condition experienced frequently and disproportionately by menopausal women and hypothesized to be potentiated by menopausal estrogen levels.

Results: The abundance of estrogen receptors in the urogenital tract explains why the natural reduction of endogenous estrogen, the hallmark of menopause, can cause or potentiate PFDs and rUTIs. A substantial body of epidemiological literature suggests an association between menopause, and PFDs and rUTIs; however, the ability to separate this association from age and other comorbid conditions makes it difficult to draw definitive conclusions on the role of menopause alone in the development and/or progression of PFDs. Similarly, the causative link between the decline in endogenous estrogen levels and the pathogenesis of PFDs and rUTIs has not been well-established.

Conclusions: Innovative human studies, focused on the independent effects of menopausal estrogen levels, uncoupled from tissue and cellular senescence, are needed.

Publication types

  • Review

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Estrogen Replacement Therapy
  • Estrogens / blood
  • Estrogens / therapeutic use
  • Female
  • Humans
  • Menopause / blood*
  • Middle Aged
  • Pelvic Floor Disorders / drug therapy
  • Pelvic Floor Disorders / epidemiology*
  • Pelvic Organ Prolapse / drug therapy
  • Pelvic Organ Prolapse / epidemiology*
  • Prevalence
  • Urinary Incontinence / drug therapy
  • Urinary Incontinence / epidemiology*
  • Urinary Tract Infections / drug therapy
  • Urinary Tract Infections / epidemiology*

Substances

  • Anti-Bacterial Agents
  • Estrogens